AMD is a leading cause of blindness in individuals over 50 years old, with dry AMD being the most common form. Geographic atrophy (GA) is an advanced stage of dry AMD characterized by progressive retinal cell degeneration. The primary objectives of the study are to assess the safety, tolerability, and evidence of activity of SGLT2 inhibitors in subjects with Geographic Atrophy associated with AMD.
Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol
Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures
Participant is male or, if female, participant is surgically sterilized or amenorrheic for at least one year
≥50 years old
Prior investigational drug use within 60 days
Use of other SGLT2 inhibitors
History of symptomatic hypotension or symptomatic hypotension (symptoms of hypotension + SBP < 90mmHg) at baseline
Type I and Type II Diabetes Mellitus